$CAPR
CAPRICOR THERAPEUTICS, INC.

2024 Q2 Form 10-Q Financial Statement

#000155837024008072 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $3.971M $4.907M $2.987M
YoY Change 1.38% 64.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.058M $4.072M $3.510M
YoY Change 7.39% 16.01% 29.24%
% of Gross Profit
Research & Development $12.50M $11.10M $7.700M
YoY Change 42.05% 44.16% 50.98%
% of Gross Profit
Depreciation & Amortization $356.9K $331.4K $230.1K
YoY Change 40.14% 44.03% 148.78%
% of Gross Profit
Operating Expenses $15.56M $15.17M $11.17M
YoY Change 33.42% 35.82% 42.65%
Operating Profit -$11.59M -$10.27M -$8.185M
YoY Change 49.62% 25.43% 4.51%
Interest Expense $591.4K $471.8K $416.4K
YoY Change 55.36% 13.3% 2998.51%
% of Operating Profit
Other Income/Expense, Net $591.4K $471.8K $416.4K
YoY Change 55.36% 13.3% 2998.53%
Pretax Income -$11.00M -$9.794M -$7.768M
YoY Change 49.32% 26.08% -0.64%
Income Tax
% Of Pretax Income
Net Earnings -$11.00M -$9.794M -$7.768M
YoY Change 49.32% 26.08% -0.64%
Net Earnings / Revenue -276.97% -199.6% -260.1%
Basic Earnings Per Share -$0.35 -$0.31 -$0.31
Diluted Earnings Per Share -$0.35 -$0.31 -$0.31
COMMON SHARES
Basic Shares Outstanding 31.81M 31.40M 25.26M
Diluted Shares Outstanding 31.84M 31.35M 25.25M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.46M $39.92M $45.17M
YoY Change -22.04% -11.63% -22.56%
Cash & Equivalents $10.69M $6.215M $10.61M
Short-Term Investments $18.77M $33.70M $34.57M
Other Short-Term Assets $837.2K $1.126M $875.1K
YoY Change 43.4% 28.65% -7.23%
Inventory
Prepaid Expenses $317.1K $291.4K
Receivables $370.0K $369.0K $547.6K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $30.67M $41.41M $46.59M
YoY Change -21.21% -11.12% -21.87%
LONG-TERM ASSETS
Property, Plant & Equipment $5.618M $5.894M $4.811M
YoY Change 17.28% 22.5% 106.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $319.6K $293.7K $268.2K
YoY Change 19.16% 9.53% -2.74%
Total Long-Term Assets $7.608M $8.033M $7.269M
YoY Change 7.36% 10.51% 37.47%
TOTAL ASSETS
Total Short-Term Assets $30.67M $41.41M $46.59M
Total Long-Term Assets $7.608M $8.033M $7.269M
Total Assets $38.28M $49.44M $53.86M
YoY Change -16.81% -8.2% -17.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.170M $6.249M $5.426M
YoY Change 20.18% 15.17% 32.39%
Accrued Expenses $792.7K $771.5K $693.7K
YoY Change 12.05% 11.22% 39.18%
Deferred Revenue $15.39M $19.36M $31.01M
YoY Change -47.49% -37.56% 219.72%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.35M $26.38M $37.13M
YoY Change -36.41% -28.95% 159.24%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M $3.376M $3.376M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $1.044M $1.249M $7.149M
YoY Change -78.02% -82.52% -68.34%
Total Long-Term Liabilities $4.420M $4.626M $10.53M
YoY Change -45.6% -56.05% -59.45%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.35M $26.38M $37.13M
Total Long-Term Liabilities $4.420M $4.626M $10.53M
Total Liabilities $26.78M $31.01M $47.66M
YoY Change -38.14% -34.93% 18.32%
SHAREHOLDERS EQUITY
Retained Earnings -$180.2M -$169.2M -$144.8M
YoY Change 18.36% 16.79% 25.0%
Common Stock $191.5M $187.3M $151.0M
YoY Change 23.74% 24.07% 7.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.50M $18.43M $6.206M
YoY Change
Total Liabilities & Shareholders Equity $38.28M $49.44M $53.86M
YoY Change -16.81% -8.2% -17.03%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$11.00M -$9.794M -$7.768M
YoY Change 49.32% 26.08% -0.64%
Depreciation, Depletion And Amortization $356.9K $331.4K $230.1K
YoY Change 40.14% 44.03% 148.78%
Cash From Operating Activities -$12.29M -$1.268M $4.210M
YoY Change 30.48% -130.13% -82.49%
INVESTING ACTIVITIES
Capital Expenditures $80.90K $608.6K $347.7K
YoY Change -65.34% 75.04% -38.75%
Acquisitions
YoY Change
Other Investing Activities $14.78M -$8.838M -$2.759M
YoY Change 120.71% 220.37%
Cash From Investing Activities $14.70M -$9.502M -$3.212M
YoY Change 127.43% 195.86% 413.58%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.067M 2.290M 3.895K
YoY Change -5.53% 58699.59% -85.82%
NET CHANGE
Cash From Operating Activities -12.29M -1.268M 4.210M
Cash From Investing Activities 14.70M -9.502M -3.212M
Cash From Financing Activities 2.067M 2.290M 3.895K
Net Change In Cash 4.474M -8.480M 1.002M
YoY Change -682.22% -946.09% -95.73%
FREE CASH FLOW
Cash From Operating Activities -$12.29M -$1.268M $4.210M
Capital Expenditures $80.90K $608.6K $347.7K
Free Cash Flow -$12.37M -$1.877M $3.862M
YoY Change 28.16% -148.6% -83.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31354629
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25247354
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001133869
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31148320
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31600183
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31600183
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M7D
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-34058
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150, San Diego
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
727-1755
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
CAPR
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31811470
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6214647
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14694857
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
33702431
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24792846
CY2024Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
369000
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
10371993
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1125844
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
995776
CY2024Q1 us-gaap Assets Current
AssetsCurrent
41411922
CY2023Q4 us-gaap Assets Current
AssetsCurrent
50855472
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5893552
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1845246
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2050042
CY2024Q1 us-gaap Other Assets
OtherAssets
293722
CY2023Q4 us-gaap Other Assets
OtherAssets
268172
CY2024Q1 us-gaap Assets
Assets
49444442
CY2023Q4 us-gaap Assets
Assets
58734327
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6248657
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6250241
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
771506
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
749112
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
19363589
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
24270465
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
26383752
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31269818
CY2024Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1249493
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486783
CY2024Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4625752
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4863042
CY2024Q1 us-gaap Liabilities
Liabilities
31009504
CY2023Q4 us-gaap Liabilities
Liabilities
36132860
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31600183
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31148320
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
31600
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
31148
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
187257063
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
181701859
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
307701
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
235813
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169161426
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159367353
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18434938
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49444442
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58734327
CY2024Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4906877
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2986696
CY2024Q1 us-gaap Revenues
Revenues
4906877
CY2023Q1 us-gaap Revenues
Revenues
2986696
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11101013
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7661519
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4071766
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3509885
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
15172779
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
11171404
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10265902
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8184708
CY2024Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
471829
CY2023Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
416442
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
471829
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
416442
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9794073
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
71888
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9722185
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7778524
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31354629
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25247354
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2290244
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3265412
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
71888
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9794073
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18434938
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2194784
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3895
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6206249
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-9794073
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7768266
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
331406
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
230101
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3265412
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2194784
CY2024Q1 capr Noncash Lease Expenses
NoncashLeaseExpenses
-10100
CY2023Q1 capr Noncash Lease Expenses
NoncashLeaseExpenses
-6452
CY2024Q1 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-10002993
CY2023Q1 capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
0
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
130068
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-44800
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
25550
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1584
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
501815
CY2024Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4906876
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
9013304
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1268440
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4210086
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
33210697
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34803580
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24373000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
32045000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
608588
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
347690
CY2024Q1 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
55729
CY2023Q1 capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
105425
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9502014
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3211695
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2290244
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3895
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2290244
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3895
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8480210
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1002286
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14694857
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6214647
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10605528
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2024Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</p>
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39900000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39500000
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2023 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191463
CY2024Q1 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
366551
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2024Q1 us-gaap Depreciation
Depreciation
331406
CY2023Q1 us-gaap Depreciation
Depreciation
230101
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8420006
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7766696
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2526454
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2206055
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5893552
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
CY2023Q1 capr Grant Income
GrantIncome
0
CY2024Q1 capr Grant Income
GrantIncome
0
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11100000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7700000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9700000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7800000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
71888
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15670163
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7971557
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31600183
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2023Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.61
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2024Q1 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.61
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2024Q1 capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2021Q2 capr Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
CY2024Q1 capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.59
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.47
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.09
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.19
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.15
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.21
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.039
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.043
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.036
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.039
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3265412
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2194784
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
21200000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
CY2024Q1 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
3
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
39700000
CY2024Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
384357
CY2023Q1 us-gaap Short Term Lease Payments
ShortTermLeasePayments
23607
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
291444
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
668233
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
914220
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
634889
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2217342
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
196343
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2020999
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
771506
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1249493
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2020999
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0740
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1800000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2024Q1 capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-008072-index-headers.html Edgar Link pending
0001558370-24-008072-index.html Edgar Link pending
0001558370-24-008072.txt Edgar Link pending
0001558370-24-008072-xbrl.zip Edgar Link pending
capr-20240331.xsd Edgar Link pending
capr-20240331x10q.htm Edgar Link pending
capr-20240331xex31d1.htm Edgar Link pending
capr-20240331xex31d2.htm Edgar Link pending
capr-20240331xex32d1.htm Edgar Link pending
capr-20240331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
capr-20240331_cal.xml Edgar Link unprocessable
capr-20240331_def.xml Edgar Link unprocessable
capr-20240331_lab.xml Edgar Link unprocessable
capr-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20240331x10q_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending